Examination of Cognitive Function in Patients Treated With Subutex
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs.
The popular treatment's goal is to "clean" the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment.
The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports)
| Condition | Intervention |
|---|---|
|
Opiate Addiction |
Other: Sexual, cognitive functional tests and measurement weight |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates |
- ASI quationarry, neurocognitive computerized tests, MMSE test, Sexual function questionnaire and satisfaction questionnaire [ Time Frame: In 2 visits during the study ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Subutex group
People who used opiates and willing to start with subutex treatment
|
Other: Sexual, cognitive functional tests and measurement weight |
Detailed Description:
People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs.
The popular treatment's goal is to "clean" the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment.
The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports) We examine people who stopped opiates and began Buprenorphine. Every participant in the study will have two visits: the first one before receiving Buprenorphine and the second one after 3 months of receiving Buprenorphine.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
People who suffer from addiction problems (opiates) and willing to start Buprenorphine treatment
Inclusion Criteria:
- People who suffer from addiction problems (opiates)
- People who willing to to start Buprenorphine treatment
- People who willing to cooperate with study tests and questionnaires
- People aged 18 to 70
Exclusion Criteria:
- People who suffer from any neurocognitive problems
- People who suffer from mental illnesses
- People who are having legal guardian
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Aviva Wolf, "Hebetim" psychiatric and psychologic clinic- private clinic |
| ClinicalTrials.gov Identifier: | NCT00687089 History of Changes |
| Other Study ID Numbers: | Subutex-214CTIL |
| Study First Received: | May 27, 2008 |
| Last Updated: | January 25, 2009 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by BeerYaakov Mental Health Center:
|
Opiates Subutex Buprenorphine Patients who addicted to opiates |
Additional relevant MeSH terms:
|
Behavior, Addictive Opioid-Related Disorders Compulsive Behavior Impulsive Behavior Substance-Related Disorders Mental Disorders Buprenorphine Analgesics, Opioid Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotic Antagonists Narcotics |
ClinicalTrials.gov processed this record on May 23, 2013